> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Baxter Debarment Reduced by 3 Years
- URL: https://www.fdaweb.com/baxter-debarment-reduced-by-3-years/
- Published: 2024-02-28T12:00:00.000Z
- Updated: 2026-09-14T14:24:03.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156449

*Federal Register* notice: FDA is issuing an order to reduce a five-year debarment against former Indivior global medical director **Timothy Baxter**. The agency says the debarment will now end 10/26/2025, three years earlier than originally ordered, due to a “mutual agreement of the parties.”

The debarment was ordered last year ([see story](https://fdaweb.com/login.php?sa=v&aid=D5153860&cate=&stid=%241%245J..o3%2F.%242a5yCC14psuGfA5DxJIVP1&ref=fdaweb.com)) over Baxter’s role in the company’s actions that introduced into interstate commerce misbranded shipments of the opioid drug Suboxone Film (buprenorphine). An earlier Justice Department [statement](https://www.justice.gov/usao-wdva/pr/opioid-manufacturer-indivior-s-former-global-medical-director-pleads-guilty-connection?ref=fdaweb.com) said that Baxter admitted that as an Indivior employee he supervised inaccurate drug safety information that was sent to the Massachusetts Medicaid agency in 2012\. Suboxone Film is approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms.